Silicone-containing derivatives of salicylic acid which have desquamating properties

ABSTRACT

The invention relates to novel compounds of the organosiloxane and organosilane type, bearing at least one function derived from salicylic acid. These novel products have, in particular, desquamating and/or anti-aging properties and may be used in topical application.

The present invention relates to novel compounds of the organosiloxaneand organosilane type, presenting the common characteristic of allhaving at least one function derived from salicylic acid. The presentinvention also relates to the use of these novel derivatives in topicalcompositions as desquamating products and/or for combating aging, aswell as to topical compositions containing these products, and to aprocess for the non-therapeutic treatment of the skin.

Products having a desquamating activity are sought in cosmetics, inparticular in antidandruff products, compositions for treating dry skin,beauty masks and for so-called "peeling" processes. These products,while allowing the removal of dead or hyperkeratinized skin, should notcause any inflammation.

In dermopharmacy, the use of desquamating and comedolytic products isalso of great value, in particular in the treatment of diseasesaffecting the stratum corneum of man or animals, such as verrucas, acne,eczema, psoriasis, ulcers, etc.

Salicylic acid is known for its desquamating properties and it isgenerally used as a desquamating agent against acne. Some of itsderivatives are also known for this activity; reference may be made inparticular to French Patent Application No. FR-A-2,581,542.

Moreover, in the course of the aging process, different signs appear inthe skin which are very characteristic of this aging, reflected inparticular by a change in the structure and function of the skin. Thesesigns are particularly pronounced on exposed areas, such as the face andthe hands, to which specific characteristics due to exposure of the skinto sunlight (actinic aging) are generally added.

Aging of the skin results from effects of intrinsic or extrinsic factorson the skin, reflected in the appearance of wrinkles and fine lines,yellowing of the skin which develops a "parchment" appearanceaccompanied by the appearance of pigmentary blemishes, this organizationof the elastin and collagen fibres leading to a loss of elasticity,flexibility and firmness, and the appearance of telangiectasias.

Some of these signs of aging are more particularly associated withintrinsic or physiological aging, that is to say "normal" agingassociated with age, whereas others are more specific to extrinsicaging, that is to say aging caused generally by the environment; thisrelates more particularly to photo-aging due to exposure to the sun, tolight or to any other radiation.

The invention is concerned with intrinsic or physiological aging as wellas extrinsic aging.

The changes in the skin due to intrinsic aging are the consequence ofgenetically programmed senescence involving endogenous factors. Thisintrinsic aging gives rise in particular to a slowing down of therenewal of skin cells, which is reflected essentially in the appearanceof clinical changes such as the reduction of the subcutaneous adiposetissue and the appearance of fine lines or wrinkles, and inhistopathological changes such as an increase in the number andthickness of elastic fibres, a loss of vertical fibres from the elastictissue membrane and the presence of large irregular fibroblasts in thecells of this elastic tissue.

In contrast, extrinsic aging results in clinical changes such as largewrinkles and the formation of a flaccid and leathery skin, andhistopathological changes such as excessive accumulation of elasticmaterial in the upper dermis and degeneration of the collagen fibres.

In EP-A-378,936 and WO-93/10756, for example, salicylic acid and certainderivatives thereof may be used to treat aging of the skin. However,some of these substances do not have all the properties required forsuitable use in cosmetic and/or dermatological compositions. Inparticular, their solubility in the various types of formulations usedis not always sufficiently high (liposolubility in particular) and theymay also have a poor resistance to water and to sweat. It is alsodesirable for these substances not to penetrate into the skin.

Thus, it has been sought to obtain products having properties that areimproved compared with existing products, in particular as regards theirliposolubility and their cosmetic nature, by fixing, via grafting(hydrosilylation), a salicylic acid group onto a macromolecular chain ofsilicone type (organopolysiloxane).

Organopolysiloxanes grafted with salicylic acid derivatives are knownfrom, for example, FR-A-1,124,824, GB-A-1,164,522, JP-A-71,002,575,FR-A-2,200,275, FR-A-2,550,787, EP-A-138,321, and EP-A-138,590. However,in all these documents, the salicylic acid derivative is connected tothe siloxane polymer in the form of a salicylate radical or alkylsalicylate, and none of these documents suggests using such polymers fordesquamating the skin.

It is known from document FR-A-2,683,455 to use the monomethyltrisilanolof salicylic acid to stimulate the localized synthesis of connectivetissue.

The present inventors have discovered, surprisingly, novelsilicon-containing derivatives of salicylic acid which have desquamatingproperties and treat aging of the skin, while at the same time beingendowed with a lipophilic nature which facilitates their use in cosmeticcompositions in any pharmaceutical form.

A first subject of the present invention is thus novelsilicon-containing derivatives of salicylic acid corresponding to one offormulae (1) to (3) below: ##STR1## in which:

R_(a) to R_(g), which are identical or different, are selected fromlinear and branched, saturated and unsaturated (C₁ -C₁₀)alkyl and (C₂-C₁₀)alkenyl radicals, phenyl radicals and 3,3,3-trifluoropropylradicals, at least 80%, on a number basis, of the radicals R_(a) toR_(g) being the methyl radical.

A denotes a monovalent radical attached directly to a silicon atom andcorresponding to formula (4): ##STR2## in which:

R₁ represents OH, a linear or branched, saturated or unsaturated (C₁C₄)alkoxyl radical or an acyloxy function of formula O(C═O)R₄, in whichR₄ represents a linear or branched (C₁ -C₈)alkyl or (C₂ -C₈)alkenylradical,

each R₂ independently represents an OH radical, a linear or branched (C₁-C₈)alkyl or (C₂ -C₈)alkenyl radical or a linear or branched (C₁-C₈)alkoxyl radical, it being possible for two adjacent R₂ radicalstogether to form an alkanedioxy group in which the alkane chain contains1 or 2 carbon atoms,

R₃ represents a radical selected from: a hydrogen atom, apharmaceutically acceptable cation, a linear or branched (C₁ -C₆)alkylor (C₂ -C₆)alkenyl radical and a benzyl radical, optionally substitutedwith a group selected from the following radicals: linear and branched(C₁ -C₆)alkyl and (C₂ -C₆)alkenyl, hydroxyl, amino, linear and branched(C₁ -C₆)alkoxy and (C₂ -C₆)alkenyloxy, halogencarboxylic acid, andlinear and branched (C₁ -C₆)alkyl carboxylate or (C₂-C₆)-alkenylcarboxylate,

when R₁ is other than OH, R₃ is H or a pharmaceutically acceptablecation,

m is selected from the integers 0, 1 and 2,

p is selected from the integers 0 and 1,

X represents O, NH, C═O, NH(C═O)NH, NH(C═O) or (C═O)NH,

n is selected from the integers 0 and 1,

Z is a linear or branched, saturated or unsaturated (C₁ -C₆)alkanediylradical, optionally substituted with a hydroxyl radical or a linear orbranched, saturated or unsaturated (C₂ -C₈)alkoxyl radical,

Y represents a hydrogen atom, a hydroxyl radical or a linear orbranched, saturated or unsaturated (C₂ -C₈)alkoxyl radical,

B₁ and B₂, which are identical or different, are selected from theradicals R_(a) to R_(g) and A defined above,

R'₁, R'₂ and R'₃, which are identical or different, are selected fromlinear or branched, saturated or unsaturated (C₁ -C₈)alkyl and (C₂-C₈)alkenyl radicals, the phenyl radical and linear or branched,saturated or unsaturated (C₁ -C₄)alkoxyl radicals,

r is an integer ranging from 0 to 50,

s is an integer ranging from 0 to 20, it being understood that if s iszero, then at least one of the radicals B₁ and B₂ denotes the radical A,

μ is an integer ranging from 1 to 6 and t is an integer ranging from 0to 10, it being understood that t+μ is greater than or equal to 3.

When compared with products already known in the art, these products areof higher liposolubility, allowing them to be introduced into fattycompositions, avoiding excessive drying out of the skin on account ofthe desquamating activity.

In formulae (1) to (3) above, A therefore represents the group derivedfrom salicylic acid which, after it is fixed to the starting siliconechain or to the starting silane, imparts to the compounds of linearorganosiloxane type (formula (1)) or cyclic organosiloxane type (formula(2)) or triorganosilane type (formula 3)) properties of desquamating andrejuvenating skin.

As emerges from formula (4) given above, attachment of the chain unit--(X)_(n) --(Z)_(p) -- to the aromatic ring of the salicylic unit, whichthus ensures connection of the salicylic unit to the silicon atom of thesilicone chain or of the silane, may, according to the presentinvention, take place in all the available positions offered by thearomatic ring.

Preferably, this attachment takes place in position 3, 4 or 5.

Similarly, attachment of the substituent unit R₂ may take place in allthe other available positions on the salicylic ring.

In formulae (1) to (3) above, the alkyl radicals may be linear orbranched and preferably selected from methyl, ethyl, n-propyl,isopropyl, n-butyl, isobutyl, tert-butyl, n-amyl, isoamyl, neopentyl,n-hexyl, n-heptyl, n-octyl, 2-ethylhexyl and tert-octyl radicals.Preferably, the radicals Ra to Rg are selected from methyl, ethyl,propyl, n-butyl, n-octyl and 2-ethylhexyl and, even more preferably, theradicals R_(a) to R_(g) represent methyl.

Preferably, the radicals R'₁, R'₂ and R'₃ are selected from methyl,ethyl, propyl, n-butyl, n-octyl and 2-ethylhexyl radicals and, morepreferably R'₁, R'₂ and R'₃ represent methyl.

According to a preferred embodiment of the invention, the alkyl radicalsB₁ and B₂ are selected from methyl, ethyl, propyl, n-butyl, n-octyl and2-ethyl-hexyl radicals and, preferably the radicals B₁ and B₂ bothrepresent methyl.

Among the compounds for formulae (1) to (3) above, it is preferred touse those corresponding to formula (1) or to formula (3), i.e., linearshort-chain organosiloxanes or triorganosilanes.

Among the linear organosiloxanes forming part of the present invention,more particularly preferred are random derivatives or derivatives inwell-defined blocks and moreover having in particular at least one, andmore preferably all, of the following characteristics:

R_(a) to R_(g) are alkyl radicals, and more preferably represent methyl,

B₁ and B₂ are alkyl radicals, and more preferably methyl (in the case ofthe linear compounds of formula (1)),

r ranges from 0 to 3; s ranges from 0 to 3 (in the case of the linearcompounds of formula (1)),

R₁ is OH,

R₃ is a hydrogen atom,

m=0, and

n=0 or X represents 0 (n=1).

More preferably, a subject of the invention is the following products:

methyl 2-hydroxy-4-(3-trimethylsilanylpropyl-oxy)benzoate,

2-hydroxy-4-(3-trimethylsilanylpropyloxy)benzoic acid,

methyl 2-hydroxy-5-(3-trimethylsilanylpropyl-oxy)benzoate,

2-hydroxy-5-(3-trimethylsilanylpropyloxy)benzoic acid,

methyl 2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy !-disiloxanyl!propyloxy!benzoate,

methyl 2-hydroxy-3- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy !-disiloxanyl!propyl!benzoate,

2-hydroxy-3- 2-methyl-3- 1,3,3,3-tetramethyl-1- (trimethylsilyl)oxy!-disiloxanyl!propyl!benzoic acid,

2-hydroxy-3- 2-methyl-3- 1,3,3,3-tetramethyl-1- (trimethylsilyl)oxy!-disiloxanyl!propyl!benzoic acid, and

2-hydroxy-5- 3- 1,3,3,3-tetramethyl-1- (trimethylsilyl)oxy!disiloxanyl!-propylamido!benzoic acid.

In order to prepare the silicone-containing salicylates of formulae (1),(2) and (3), the process may be performed conventionally using ahydrosilylation reaction, namely:

    .tbd.Si--H+CH.sub.2 ═CY--→.tbd.Si--CH.sub.2 --CHY--

starting with the corresponding silicone or silane, in which all theradicals A are hydrogen atoms. This starting silicone is referred tohereinbelow as the SiH-containing derivative; the SiH groups may bepresent in the chain and/or at the ends of the silicone chain. TheseSiH-containing derivatives are products that are well known in thesilicone industry and are generally commercially available. They aredescribed, for example, in U.S. Pat. Nos. 3,220,972, 3,697,473 and4,340,709, the disclosures of which are hereby incorporated byreference.

This SiH-containing derivative may thus be represented either by formula(1b) below: ##STR3## in which R_(a) to R_(g), r and s have the meaninggiven above for formula (1) and the radicals B'₁ and B'₂, which areidentical or different, are selected from the radicals R_(a) to R_(g)and a hydrogen atom,

or by formula (2b) below: ##STR4## in which R_(c), R_(e), t and u havethe meaning given above for formula (2), or by formula (3b) below

    HSiR'.sub.1 R'.sub.2 R'.sub.3                              ( 3b)

in which R'₁,R'₂, and R'₃ have the same meaning as in formula (3).

A standard hydrosilylation reaction is thus carried out on thisSiH-containing derivative of formula (1b), (2b) or (3b), performed inthe presence of a catalytically effective amount of a platinum catalyst,on an organic derivative of salicylic acid of formula (4b) below:##STR5## in which R₁, R₂, X, Z, Y, n, m and p have the meaning givenabove for formula (4) and R₃ represents a radical selected from: linearand branched (C₁ -C₆)alkyl and (C₂ -C₆)alkenyl radicals and benzylradicals.

The products corresponding to formulae (1), (2) and (3) in which R₃ is ahydrogen atom are prepared from derivatives of the same formula inwhich:

R₃ is an alkyl radical, by basic hydrolysis in alcoholic medium, or

R₃ is a benzyl radical, by catalytic hydrogenation in the presence of acatalyst of the palladium-on-charcoal type, or with a hydrogen-transferagent such as cyclohexene.

Processes which are suitable for preparing the products of formula (4b)above are described in particular in U.S. Pat. Nos. 4,316,033 and4,328,346, the disclosures of which are incorporated herein byreference.

Moreover, the details of the operating conditions to follow to carry outthe hydrosilylation reaction between the compounds of formula (1b) or(2b) above with the compound of formula (4b) above are given inEP-A-0,392,883, the disclosure of which is hereby incorporated byreference.

Another subject of the present invention is the use of thesilicon-containing derivatives of salicylic acid corresponding to one offormulae (1) to (3), in, or for the manufacture of, a cosmetic ordermatological composition to promote desquamation of human skin and/orto stimulate epidermal renewal.

Another subject of the present invention is the use of thesilicon-containing derivatives of salicylic acid corresponding to one offormulae (1) to (3) for treating intrinsic and extrinsic aging of humanskin.

Another subject of the present invention is the use of thesilicon-containing derivatives of salicylic acid corresponding to one offormulae (1) to (3) in, or for the manufacture of, a cosmetic ordermatological composition, in particular to combat wrinkles and/or finelines and/or actinic blemishes and/or skin dyschromias and/or dermatitisand/or scars on human skin.

Another subject of the invention is the use of the silicon-containingderivatives of salicylic acid corresponding to one of the formulae (1)to (3) in, or for the manufacture of, an antibacterial or antisuncosmetic or dermatological composition and/or a cosmetic ordermatological composition for protecting human skin against freeradicals.

An in vitro test of the efficacy of the desquamation was carried out onkeratinocytes using 5-n-octanoylsalicylic acid (compound C₁),2-hydroxy-4-(3-trimethylsilanylpropyloxy)benzoic acid (compound C₂) and2-hydroxy-5-(3-trimethylsilanylpropyloxy)benzoic acid (compound C₃). C₁is a known powerful desquamating active agent, but not part of thepresent invention. C₂ and C₃ are compounds of the present invention.

The principle of the test rests on the fact that desquamation is knownto induce the release of corneocytes. The desquamating power of the testproduct should be proportionately greater the larger the number ofcorneocytes released.

The test procedure was as follows: keratinocytes were obtained byseparating the epidermis from skin biopsies, and these keratinocyteswere dissociated by enzymatic action with trypsin and cultured at aconcentration of 2×10⁵ cells/ml. Growth and differentiation of thekeratinocytes were obtained by culturing for 10 to 20 days in specificmedium.

Next, after removing the culture medium, the test product was added andthe activity of the product evaluated. To do this, two samples weretaken at T₀ and T₆₀, i.e., before addition of the product and 60 minutesafter this addition, and the samples thus taken were analysed on a flowcytometer to count the population of corneocytes. With the flowcytometer, the populations of corneocytes and keratinocytes weredifferentiated by treatment with acridine orange which is specific forthe DNA in cells, which binds to the cell nuclei and thereforeexclusively reveals the presence of the keratinocytes.

The cell detachment index was determined by the difference between T₆₀and T₀.

The same measurement was taken for a control containing no test productsince the experiment inevitably produces the release of corneocytes,even in the absence of active agent. The variation of the controlarbitrarily set the standard at 100%.

The results are collated in the following table:

    ______________________________________                                                Compound     Compound  Compound                                       Control C.sub.1      C.sub.2   C.sub.3                                        ______________________________________                                        0%      103%         157%      135%                                           ______________________________________                                    

These results show clearly that the inventive compounds2-hydroxy-4-(3-trimethylsilanyl-propyloxy)benzoic acid and2-hydroxy-5-(3-trimethylsilanylpropyloxy)-benzoic acid, at aconcentration equal to that of the non-inventive 5-n-octanoylsalicylicacid, which is known as being a powerful desquamating active agent, weremuch more active than the latter.

Another subject of the invention is a non-therapeutic treatment processfor the skin intended to desquamate human skin, which involves applyingto this skin a composition containing at least one silicon-containingderivative of salicylic acid corresponding to one of formulae (1), (2)and (3) in a cosmetically and/or dermatologically acceptable medium.

Another subject of the invention is a process for the non-therapeutictreatment of aging of the skin, which involves applying to human skin acomposition containing at least one silicon-containing derivative ofsalicylic acid as defined above, in a cosmetically and/ordermatologically acceptable medium.

Another subject of the invention is cosmetic and/or dermatologicalcompositions, characterized in that they comprise at least onesilicon-containing derivative of salicylic acid corresponding to one offormulae (1) to (3).

The composition of the invention contains a cosmetically ordermatologically acceptable medium, i.e., a medium which is compatiblewith the skin, the nails, the mucous membranes, the tissues and thehair. The composition comprising the silicon-containing derivative ofsalicylic acid may be applied topically to the face, the neck, the hair,the mucous membranes, the nails or to any other area of body skin.

The solubility of the silicon-containing derivatives of salicylic acidaccording to the invention in organic media was evaluated by comparingthe solubility of 5-n-octanoylsalicylic acid with inventive compounds:

2-hydroxy-4-(3-trimethylsilanyl propyloxy)benzoic acid (C₂),

2-hydroxy-5-(3-trimethylsilanyl propyloxy)benzoic acid (C₃),

2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethyl-silyl)oxy!disiloxanyl!propyloxy!benzoic acid (C₄), and

2-hydroxy-3- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!propyl!benzoic acid (C₅),

in a mixture of caprylic acid and capric acid triglyceride, marketedunder the name MIGLYOL 812 by the company Huls. Solubility at roomtemperature:

C₁ :<1.5%

C₂ :2%

C₃ :7%

C₄ :6%

C₅ :>20%

Thus, the solubility of the inventive compounds is greater than that ofthe non-inventive compound C₁.

Because the derivatives according to the invention are more soluble inoils than the non-silicon-containing derivatives of salicylic acid, theyare more readily introduced into aqueous-lipid media and are of greaterefficacy when they are solubilized in these media in order then to beapplied to the skin.

Similarly favorable desquamating and solubility results may be obtainedwith all the products according to the invention.

The compositions according to the invention may be in any form which issuitable for topical application, in particular in the form of aqueous,aqueous-alcoholic or oily solutions, dispersions of the lotion or serumtype, aqueous, anhydrous or oily gels, emulsions of liquid orsemi-liquid consistency of milk type, obtained by dispersing a fattyphase in an aqueous phase (O/W) or conversely (W/O), suspensions oremulsions of soft, semi-solid or solid consistency of the cream or geltype, microemulsions, or alternatively microcapsules, microparticles orvesicle dispersions of ionic and/or nonionic type. These compositionsare prepared according to the usual methods.

They may also be used for the hair in the form of aqueous, alcoholic oraqueous-alcoholic solutions or in the form of creams, gels, emulsions orfoams or alternatively in the form of aerosol compositions alsocontaining a propellant under pressure.

The amounts of the various constituents of the compositions according tothe invention are those used conventionally in the fields considered.

In the compositions according to the invention, the products accordingto formulae (1), (2) and (3) preferably may be used in an amount rangingfrom 0.2 to 20% by weight relative to the total weight of thecomposition, and more preferably in an amount ranging from 0.5 to 10%,and still more preferably in an amount ranging from 0.5 to 5% by weightrelative to the total weight of the composition.

These compositions preferably constitute protective, treatment or carecreams for the skin or the mucous membranes, for the face, for the handsor for the body, protective or care body milks, care or treatmentlotions, gels or foams for the skin and the mucous membranes or forcleansing the skin.

The compositions may also comprise solid preparations constituting soapsor cleansing bars.

When the composition of the invention is an emulsion, the proportion ofthe fatty phase may range from 5% to 80% by weight, and preferably from5% to 50% by weight, relative to the total weight of the composition.The oils, the emulsifiers and co-emulsifiers used in the composition inemulsion form are selected from those conventionally used in thecosmetic or dermatological field. The emulsifier and the co-emulsifiersare preferably present in the composition in an amount ranging from 0.3%to 30% by weight, and preferably from 0.5 to 20% by weight, relative tothe total weight of the composition. The emulsion may, in addition,contain lipid vesicles.

When the composition is an oily gel or solution, the amount of oil maybe up to 90% by weight of the total weight of the composition.

In a known manner, the composition of the invention may also containadjuvants which are common in the cosmetics and dermatological fields,such as hydrophilic or lipophilic gelling agents, hydrophilic orlipophilic active agents other than those of the invention, preservingagents, antioxidants, solvents, fragrances, sequestering agents, fillersand dyestuffs. The amounts of these various adjuvants are those usedconventionally in the fields considered and, for example, range from0.01% to 20% weight percent with respect to the total weight of thecomposition. Depending on their nature, these adjuvants may beintroduced into the fatty phase, into the aqueous phase and/or into thelipid spherules.

As oils which can be used in the invention, mention may be made ofmineral oils (liquid petro-latum), plant oils (karite oil, sweet almondoil), animal oils, synthetic oils, silicone oils (cyclo-methicone) andfluoro oils (perfluoropolyethers). Fatty alcohols, fatty acids (stearicacid) and waxes (paraffin wax, carnauba wax, beeswax) may also be usedas fatty substances.

As emulsifiers which can be used in the invention, mention may be madeof Polysorbate 60 and sorbitan stearate sold under the trade names TWEEN60 and SPAN 60 respectively by the company ICI.

As solvents which can be used in the invention, mention may be made oflower alcohols, in particular ethanol and isopropanol, and propyleneglycol.

As hydrophilic gelling agents, mention may be made of carboxyvinylpolymers (carbomer), acrylic copolymers such as acrylate/alkylacrylatecopolymers, polyacrylamides, polysaccharides such ashydroxypropyl-cellulose, natural gums (xanthan) and clays, and, aslipophilic gelling agents, mention may be made of modified clays such asbentones, fatty acid metal salts such as aluminium stearates,hydrophobic silica, polyethylenes and ethylcellulose.

Proteins or protein hydrolysates, amino acids, polyols, urea, allantoin,sugars and sugar derivatives, water-soluble vitamins, starch, bacterialor plant extracts, in particular extracts of Aloe vera, and antisepticsmay be used as hydrophilic active agents.

Tocopherol (vitamin E) and derivatives thereof, essential fatty acids,ceramides and essential oils may be used as lipophilic active agents.

It is possible, inter alia, to combine the acids with active agentsintended in particular for the prevention and/or treatment of skincomplaints. Among these active agents, mention may be made, by way ofexample, of:

agents which modify skin differentiation and/or proliferation and/orpigmentation, such as vitamin D and derivatives thereof, oestrogens suchas oestradiol, kojic acid and hydroquinone; and

anti-free-radical agents, such as a-tocopherol and esters thereof,superoxide dismutases, certain metal-chelating agents and ascorbic acidand esters thereof.

It is possible, moreover, to combine with the silicon-containingderivative of salicylic acid according to the invention antagonists ofsubstance P and/or of CGRP (Calcitonin Gene Related Peptide) such asIris pallida and strontium salts, in particular strontium chlorides andnitrates, or antagonists of substance P and/or of CGRP such as thosedescribed in two French patent applications assigned to the presentassignee, one filed under the number 95/00,900, the other publishedunder the number FR-A-2,719,476, the disclosures of which areincorporated herein by reference. Such a combination makes it possibleto guarantee complete tolerance of these compositions, even by verysensitive skins.

The cosmetic or dermatological treatment process of the invention may becarried out in particular by applying the hygiene, cosmetic ordermatological compositions as defined above, according to the usualtechnique for using these compositions, such as, for example,application of creams, gels, sera, ointments, lotions or milks to theskin, the scalp, the nails and/or the mucous membranes.

The examples which follow illustrate the invention without limiting thescope thereof.

EXAMPLES EXAMPLE 1

Preparation of methyl 2-hydroxy-4-(3-trimethyl-silanylpropyloxy)benzoate

To a solution of methyl 2,4-dihydroxy benzoate (16.8 g, 0.1 mol) andpotassium carbonate (15.2 g, 0.11 mol) in 100 ml of DMF, under anitrogen atmosphere at 80° C., was added chloropropyltrimethyl-silane(16.6 g, 0.11 mol) dropwise over 10 minutes. The mixture was heated at90° C. for 4 hours. It was cooled and poured into 200 ml of water. Themixture was extracted with diisopropyl ether. The organic phase waswashed with water, dried over sodium sulphate and then concentrated.After chromatography on silica of the yellow oil obtained (eluent: 50/50heptane/CH₂ C'₂), 28.2 g of methyl2-hydroxy-4-(3-tri-methylsilanylpropyloxy)benzoate were recovered(yield: 57%) in the form of a white powder.

m.p.: 32°-33° C.

UV (ethanol) λ_(max) =298 nm, ε_(max) =7325

Elemental analysis for C₄ H₂₂ O₄ Si

calculated: C 59.5 H 7.8 Si 10.0

found: C 59.3 H 7.8 Si 10.2

EXAMPLE 2

Preparation of 2-hydroxy-4-(3-trimethylsilanylpro-pyloxy)benzoic acid

The product of Example 1 (16 g, 0.057 mol) in a 90:10 ethanol/watermixture (100 ml) was heated at 50° C. in the presence of potassiumhydroxide (2 g) for 4 hours. The mixture was cooled and was acidifiedwith dilute hydrochloric acid. The precipitate formed was washed withwater and dried under vacuum. 15.2 g (yield: 93%) of2-hydroxy-4-(3-trimethylsilanylpro-pyloxy)benzoic acid were obtained inthe form of a white powder.

m.p.: 187° C.

UV (ethanol) λ_(max) =295 nm, ε_(max) =6350

Elemental analysis for C₁₃ H₂ O₄ Si

theory: C 58.2 H 7.5 Si 10.4

found: C 58.3 H 7.4 Si 10.1

EXAMPLE 3

Preparation of methyl 2-hydroxy-5-(3-trimethyl-silanylpropyloxy)benzoate

To a mixture of methyl gentisate (16.8 g, 0.1 mol) and potassiumcarbonate (15.2 g, 0.11 mol) in 80 ml of DMF, under a nitrogenatmosphere at 80° C., was added chloropropyltrimethylsilane (16.6 g,0.11 mol) dropwise over 20 minutes. The mixture was heated at 90° C. for8 hours. It was cooled and poured into 200 ml of water. The mixture wasextracted with diisopropyl ether. The organic phase was washed withwater, dried over sodium sulphate and then concentrated. Afterchromatography on silica of the yellow oil obtained (eluent: 90/10heptane/CH₂ Cl₂), 3.3 g of a clean fraction of methyl2-hydroxy-5-(3-trimethylsilanylpropyloxy)benzoate were recovered.

UV (ethanol) λ_(max) =335 nm, ε_(max) =4500

Elemental analysis for C₁₄ H₂₂ O₄ Si

calculated: C 59.5 H 7.8 Si 9.9

found: C 59.5 H 7.9 Si 9.7

EXAMPLE 4

Preparation of 2-hydroxy-5-(3-trimethylsilanylpro-pyloxy)benzoic acid

The product of Example 3 (3.3 g, 0.012 mol) in a 50/50 ethanol/watermixture (15 ml) was maintained at reflux for 3 hours in the presence ofpotassium hydroxide (2 g). The mixture was cooled and acidified to pH 1with 10% hydrochloric acid. The precipitate formed was washed with waterand dried under vacuum. It was recrystallized from a 50/50methanol/water mixture (30 ml). 2 g (yield: 64%) of2-hydroxy-5-(3-trimethylsilanylpro-pyloxy)benzoic acid were obtained inthe form of a white powder.

m.p.: 115°-116° C.

UV (ethanol) λ_(max) =330 nm, ε_(max) =4335

Elemental analysis for C₁₃ H₂₀ O₄ Si

theory: C 58.2 H 7.5 Si 10.4

found: C 58.1 H 7.5 Si 10.2

EXAMPLE 5

Preparation of methyl 2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disilox-anyl!propyloxy!benzoate

a) First step: preparation of methyl2-hydroxy-4-(2-methylallyloxy)benzoate:

Methyl chloride (14.26 ml, 0.145 mol) was added dropwise over 30 minutesto a mixture of methyl 2,4-dihydroxybenzoate (24.5 g, 0.145 mol) andpotassium carbonate (20.14 g, 0.145 mol) in 90 ml of DMF brought to 75°C. The mixture was left at 75° C. for 3 hours. It was cooled and pouredinto ice-water. The mixture was extracted with dichloromethane and theorganic phase was washed with water and dried over sodium sulphate, thesolvent was evaporated off and the residue was dried under vacuum. Thepale yellow oil obtained was purified on silica (eluent: 60/40 heptane/CH₂ Cl₂). The head fractions were pooled to give 13.4 g of the desiredproduct in the form of a colourless oil.

b) Second step: preparation of methyl 2-hydroxy-4- 2-methyl-3-1,3,3,3-tetramethyl-1-(trimethyl-silyl)oxy!disiloxanyl!propyloxy!benzoate:

To a solution of the above derivative (13.4 g, 0.06 mol) and catalyst(complex containing 3-3.5 wt % Pt in cyclovinylmethylsiloxane, from HulsPetrarch PC085: 100 μl) in 50 ml of dry toluene brought to 100° C., wereadded 14.12 g of heptamethyltrisiloxane dropwise over 10 minutes. Themixture was left at this temperature for 30 minutes. The reactionmixture was concentrated and chromatography was then carried out onsilica under pressure (eluent: 85/15 heptane/CH₂ Cl₂). 25 g (yield: 93%)of methyl 2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!propyl-oxy!benzoate were thus recoveredin the form of a very pale yellow oil.

UV (ethanol) λ_(max) =298 nm, ε_(max) =7340

Elemental analysis for C₁₉ H₃₆ O₆ Si₃

theory: C 51.3 H 8.2 Si 18.9

found: C 51.6 H 8.2 Si 19.0

EXAMPLE 6

Preparation of methyl 2-hydroxy-3- 2-methyl-3- 1,3,3,3-tetramethyl- 1-(trimethylsilyl)oxy!disilox-anyl!propyl!benzoate

a) First step: Preparation of methyl 2-(2-methylallyloxy)benzoate:

To a mixture of methyl 2-hydroxybenzoate (60 g, 0.394 mol) and potassiumcarbonate (52.6 g, 0.398 mol) in 240 ml of DMF maintained at 70° C. wasadded methyallyl chloride (39 ml, 0.398 mol) dropwise over 20 minutes.The mixture was left for 5 hours at 70° C. It was cooled and theinorganic salts were removed by filtration. The DMF was evaporated offunder vacuum. The expected derivative was obtained in the form of a palebrown oil (74.6 g, yield: 92%).

b) Second step: preparation of methyl2-hydroxy-3-(2-methylallyl)benzoate:

All of the above derivative was heated at 190° C. under nitrogen for 10hours. This crude reaction product was cooled and distilled undervacuum. The fraction which distilled at 68°-70° C. under a vacuum of 0.2mmHg and which corresponded to methyl2-hydroxy-3-(2-methylallyl)benzoate (63.4 g, yield: 70%) was collected.

c) Third step: preparation of methyl 2-hydroxy-3- 2-methyl-3-1,3,3,3-tetramethyl-1- (trimethyl-silyl)oxy!disiloxanyl!propyl benzoate

To a solution of 25 g (0.121 mol) of the above derivative and 100 μl ofcatalyst (complex containing 3-3.5% by weight of platinumcyclovinylmethylsiloxane marketed by the company Huls Petrarch under thereference PC085) in 80 ml of toluene at a temperature of 100° C. wereadded 28.4 g of heptamethylsiloxane dropwise over 2 hours. The mediumwas stirred at this temperature for 1 hour and was then concentratedunder vacuum, and the product was purified by chromatography on a columnof silica (eluent: 80/20 heptane/CH₂ Cl₂). 38 g (yield: 73%) of methyl2-hydroxy-3- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethyl-silyl)oxy!disiloxanyl!propyl!benzoate were thus recovered inthe form of a pale yellow oil.

UV (ethanol) λ_(max) =313 nm, ε_(max) =4615

Elemental analysis for Cl₉ H₃ 6O₅ Si₃

theory: C 51.2 H 8.5 Si 19.65

found: C 53.2 H 8.5 Si 19.4

EXAMPLE 7

Preparation of benzyl 2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethyl-silyl)oxy!disiloxanyl!propyloxy!benzoate

a) First step: preparation of benzyl 2,4-dihydroxybenzoate:

To 76.8 g of the potassium salt of resorcylic acid (0.4 mol) in 500 mlof 95% of ethanol were added 50 ml of benzyl chloride (0.42 mol). Themixture was left at reflux for 2 hours, concentrated to one-half and 500ml of water were then added. The oil which separated after settling hadtaken place was washed with sodium bicarbonate solution and then withheptane. The resulting solid was dried under vacuum and used withoutfurther purification in the following step.

b) Second step: preparation of benzyl2-hydroxy-4-(2-methylallyloxy)benzoate:

To a mixture of 17 g of benzyl 2,4-dihydroxybenzoate (0.07 mol) and 10 gof potassium carbonate (0.077 mol) in 60 ml of DMF brought to 70° C.were added 6.81 ml of methyallyl chloride (0.07 mol) dropwise over 1hour. The mixture was left at 70° C. for 2 hours. It is cooled to about40° C. and the salts are filtered off. The salts were washed with DMF.The liquids were combined, and the solvent was evaporated off. A brownoil was obtained which was purified on silica (eluent: 70/30 heptane/CH₂Cl₂). The head fractions were pooled to give 12 g (yield: 57%) of benzyl2-hydroxy-4-(2-methylallyloxy)benzoate in the form of a colourless oil.

c) Third step: preparation of benzyl 2-hydroxy-4- 2-methyl-3-1,3,3,3-tetramethyl-1-(trimethylsilyl)-oxy!disiloxanyl!propyloxy!benzoate:

To a solution of 12 g of the above derivative (0.04 mol) and 100 μl ofcatalyst (complex containing 3-3.5 wt % Pt in cyclovinylmethylsiloxanefrom Huls Petrarch PC085) in 40 ml of dry toluene brought to 100° C.were added 9.45 g of heptamethyltrisiloxane dropwise over 30 minutes.The mixture was left at this temperature for 6 hours. The reactionmixture was concentrated and was then chromatographed on silica underpressure (eluent: 80/20 heptane/CH₂ Cl₂). 17.2 g (yield: 82%) of benzyl2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)-oxy!disiloxanyl!propyloxy!benzoate were thus obtainedin the form of a colourless oil.

UV (ethanol) λ_(max) =298 nm, ε_(max) =8 130

Elemental analysis for C₂₅ H₄₀ O₆ Si₃

theory: C 57.6 H 7.7 Si 16.2

found: C 57.3 H 7.9 Si 16.4

EXAMPLE 8

Preparation of 2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!-propyloxy!benzoic acid

A mixture of 12 g of benzyl 2-hydroxy-4-(2-methyl-3-1,3,3,3-tetramethyl-1-(trimethylsilyl)-oxy!disiloxanyl!propyloxy!benzoate (0.023 mol), ethanol(40 ml), cyclohexene (12 ml) and 10% palladium-on-charcoal (1.2 g) wasmaintained at reflux for 1 hour. The mixture was cooled and was rinsedwith ethanol. The fluids were concentrated and the resulting product wasrecrystallized from a 50/50 water/ethanol mixture to give the2-hydroxy-4- 2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!propyloxy!benzoic acid in the form of awhite powder.

m.p.: 117°-118° C.

UV (ethanol) λ_(max) =294 nm, εmax=6 650

Elemental analysis for C₁₈ H₃₄ O₆ Si₃

theory: C 50.1 H 8.0 Si 19.6

found: C 49.9 H 8.0 Si 19.9

EXAMPLE 9

Preparation of 2-hydroxy-3- 2-methyl-3-1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!propyl!-benzoicacid

a) First step: preparation of benzyl 2-(2-methylallyl-oxy)benzoate

To a mixture of benzyl 2-hydroxy benzoate (114.1 g, 0.5 mol) andpotassium carbonate (66.8 g, 0.505 mol) in 300 ml of DMF brought to 70°C. was added methallyl chloride (51.4 ml, 0.505 mol) dropwise over 20minutes. The mixture was left at 70° C. for 3 hours. It was cooled toabout 40° C. and the salts were filtered off. The salts were washed withDMF. The fluids were combined and the solvent was evaporated off. 140 g(yield: 100%) of a brown oil of benzyl 2-(2-methylallyloxy)benzoate areobtained, which product was used without further purification in thefollowing step.

b) Second step: preparation of benzyl2-hydroxy-3-(2-methylallyl)benzoate:

The above derivative was heated at 190° C. for 8 hours. After cooling,the reaction mixture was subjected to fractional distillation. Thefraction which passed at 85°°90° C. under a vacuum of 0.4 mm Hg wasrecovered. 105 g (yield: 90%) of benzyl2-hydroxy-3-(2-methyl-3-allyl)benzoate were thus obtained in the form ofa colourless oil.

c) Third step: preparation of benzyl 2-hydroxy-3- 2-methyl-3-1,3,3,3-tetramethyl-1- (trimethylsilyl)oxy!-disiloxanyl!propyl!benzoate:

To a solution of the above derivative (59 g, 0.209 mol) and catalyst(complex containing 3-3.5 wt % Pt in cyclovinylmethylsiloxane from HulsPetrarch PC085: 200 μl) in 100 ml of dry toluene brought to 80° C. wereadded 48.83 g of heptamethyltrisiloxane dropwise over 4 hours. Themixture was left at this temperature for 1 hour. The reaction mixturewas concentrated and 104 g of a crude pale yellow oil were obtained.This oil (9 g) was purified by chromatography on silica under pressure(eluent: 70/30 heptane/CH₂ Cl₂). 7.8 g of benzyl 2-hydroxy-3-2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!propyl!benzoate were thus recovered inthe form of a colourless oil.

UV (ethanol) λ_(max) =314 nm, εmax=5 550

Elemental analysis for C₂₅ H₄₀ O₅ Si₃

theory: C 59.5 H 8.0 Si 16.7

found: C 59.5 H 7.9 Si 17.0

EXAMPLE 10

Preparation of 2-hydroxy-3- 2-methyl-3-1,3,3,3-tetramethylsilyl)oxy!disiloxanyl!propyl!benzoic acid

A mixture of the above crude oil of benzyl 2-hydroxy-3- 2-methyl-3-1,3,3,3-tetramethyl-1- (trimethylsilyl)oxy!disiloxanyl!propyl!benzoate(11.61 g, 0.023 mol), ethanol (40 ml), cyclohexene (12 ml) and 10%palladium-on-charcoal (1.2 g) was maintained at reflux for 1 hour. Themixture was cooled and rinsed with ethanol. The liquids wereconcentrated and the pale yellow oil obtained was purified bychromatography on silica under pressure (eluent: 80/20/0.2 CH₂ Cl₂/ethyl acetate/acetic acid) to give 7.5 g (yield: 78%) of 2-hydroxy-3-2-methyl-3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!-propyl!benzoic acid in the form of acolourless oil.

UV (ethanol) λ_(max) =310 nm, ε_(max) =4 550

Elemental analysis for C₁₈ H₃₄ O₅ Si₃

theory: C 52.1 H 8.3 Si 20.3

found: C 52.2 H 8.2 Si 20.4

EXAMPLE 11

Preparation of 2-hydroxy-5- 3- 1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy!disiloxanyl!-propylamido!benzoic acid

To a solution of 4-hydroxyisophthalic acid (5 g, 0.0275 mol) in DMF (25ml) at 200° C. was added thionyl chloride (2.2 ml, 0.03 mol), over 10minutes, and the mixture was left to react for 1 hour. This yellowsolution was poured over 1 hour into a mixture of triethylamine (6.1 g,0.06 mol) and heptamethylaminopropyltrisiloxane (8.4 g, 0.03 mol). Themixture, which became heterogenous, was left stirring for 6 hours at 20°C.

This reaction mixture was poured into water. The gummy paste obtainedwas triturated with water and then with dichloromethane. The precipitateobtained was recrystallized from an ethanol/water mixture to give 2.5 g(yield: 20%) of 2-hydroxy-5- 3- 1,3,3,3-tetramethyl- 1-(trimethyl-silyl)oxy!disiloxanyl!propyl-amido!benzoic acid in the formof a white powder.

m.p.: 222°-224° C.

UV (ethanol) λ_(max) =308 nm, ε_(max) =100

Elemental analysis for C₁₈ H₃₃ NO₆ Si₃

theory: C 48.7 H 7.5 N 3.1 Si 19.0

found: C 48.9 H 7.4 N 2.9 Si 19.0

COMPOSITION EXAMPLE

This example illustrates the invention. The proportions indicated arepercentages by weight.

    ______________________________________                                        Phase A:                                                                      2-Hydroxy-4-(3-trimethylsilanylpropyloxy)-                                                            2.5                                                   benzoic acid                                                                  Sweet almond oil        14.5                                                  Karite oil              7.0                                                   PPG-3 myristyl ether (Emcol 249-3k)                                                                   5.0                                                   Preserving agent (propyl paraben)                                                                     0.1                                                   Polysorbate 60 (Tween 60)                                                                             2.5                                                   Sorbitan stearate (Span 60)                                                                           2.5                                                   Phase B:                                                                      Cyclomethicone          4.0                                                   Xanthan gum             0.2                                                   Carboxyvinyl polymer    0.5                                                   Phase C:                                                                      Triethanolamine (neutralizing agent)                                                                  0.5                                                   Water                   2.0                                                   Phase D:                                                                      Preserving agent (methyl paraben)                                                                     0.2                                                   Glycerol                5.0                                                   Water qs                100                                                   ______________________________________                                    

The constituents of phase A were melted at 85° C., then phase A wascooled to 70° C. and phases B, then C and D were introduced therein withstirring. The mixture was cooled to room temperature. A day cream wasobtained which gave rise to desquamation of the skin and made the skinlook younger and smoother than before the treatment.

We claim:
 1. A compound having formula (3) below

    A--SiR'.sub.1 R'.sub.2 R'.sub.3

in which: A denotes a monovalent radical attached directly to a silicon atom and corresponding to formula (4): ##STR6## in which: R₁ is OH, a linear or branched, saturated or unsaturated (C₁ -C₄)alkoxyl radical or an acyloxy function of formula O(C═O)R₄, in which R₄ is a linear or branched (C₁ -C₈) alkyl or (C₂ -C₈)alkenyl radical, each R₂ independently is OH, a linear or branched (C₁ -C₈)alkyl or (C₂ -C₈)alkenyl radical or a linear or branched (C₁ -C₈)alkoxyl radical, wherein two adjacent R₂ radicals can optionally together form an alkanedioxy group in which the alkane chain contains 1 or 2 carbon atoms, R₃ is H, a pharmaceutically acceptable cation, a linear or branched (C₁ -C₆)alkyl or (C₂ -C₆)alkenyl radical, or a benzyl radical optionally substituted with a linear or branched (C₁ -C₈)alkyl or (C₂ -C₆)alkenyl radical, a hydroxyl radical, an amino radical, a linear or branched (C₁ -C₆)alkoxy or (C₂ -C₆)alkenyloxy radical, a halogen, a carboxylic acid, or a linear or branched (C₁ -C₆)alkylcarboxylate or (C₂ -C₆)alkenyl carboxylate, with the proviso that when R₁ is other than OH, R₃ is H or a pharmaceutically acceptable cation, m is 0, 1 or 2, p is 0 or 1, X is O, NH, C═O, NH(C═O)NH, NH(C═O) or (C═O)NH, n is O or 1, Z is a linear or branched, saturated or unsaturated (C₁ -C₆)alkanediyl radical, optionally substituted with a hydroxyl radical or a linear or branched, saturated or unsaturated (C₂ -C₃)alkoxyl radical, Y is H, a hydroxyl radical, or a linear or branched, saturated or unsaturated (C₂ -C₈)alkoxyl radical, R'₁, R'₂ and R'₃ are identical or different and are independently selected from linear and branched, saturated and unsaturated (C₁ -C₈)alkyl and (C₂ -C₈)alkenyl radicals, phenyl radicals, and linear and branched, saturated and unsaturated (C₁ -C₄)alkoxyl radicals.
 2. A compound according to claim 1, wherein the chain unit --(X)_(n) --(Z)_(p) -- in formula (4) is attached to the aromatic ring in position 3, 4 or
 5. 3. A compound according to claim 1, wherein said radicals R'₁, R'₂ and R'₃ are independently selected from methyl, ethyl, propyl, n-butyl, n-octyl and 2-ethylhexyl radicals.
 4. A compound according to claim 3, wherein said radicals R'₁, R'₂ and R'₃ all are methyl radicals.
 5. A compound according to claim 1, wherein R₁ is OH.
 6. A compound according to claim 1, wherein R₃ is a hydrogen atom.
 7. A compound according to claim 1, wherein m is
 0. 8. A compound according to claim 1, wherein n is 0 or 1 and X is O.
 9. A compound according to claim 1, wherein said compound ismethyl 2-hydroxy4-(3-trimethylsilanylpropyl-oxy)benzoate, 2-hydroxy4-(3-trimethylsilanylpropyloxy)benzoic acid, methyl 2-5(3-trimethylsilanylpropyl-oxy)benzoate, or 2-hydroxy-5-(3-trimethylsilanylpropyloxy)benzoic acid.
 10. A method of promoting desquamation of human skin and/or of stimulating epidermal renewal, comprising the step of applying to said skin a cosmetic or dermatological composition comprising a compound according to claim
 1. 11. A method of treating intrinsic or extrinsic aging of human skin, comprising the step of applying to said skin an effective amount of a composition comprising at least one compound according to claim
 1. 12. A method of treating aging or combating wrinkles, fine lines, actinic blemishes, skin dyschromias, dermatitis and/or scars on human skin, comprising the step of applying to the skin a cosmetic or dermatological composition comprising a compound according to claim
 1. 13. A method of preparing an antibacterial cosmetic or dermatological composition, comprising the step of including in said composition a compound according to claim
 1. 14. A method of preparing an antisun cosmetic or dermatological composition, comprising the step of including in said composition a compound according to claim
 1. 15. A method of protecting human skin against free radicals, comprising the step of applying to the skin a cosmetic or dermatological composition comprising a compound according to claim
 1. 16. A treatment process for desquamating the skin, comprising the step of applying to human skin a composition comprising, in a cosmetically and/or dermatologically acceptable medium, an effective amount of at least one compound according to claim
 1. 17. A process for treating the aging of human skin, comprising the step of applying to human skin a composition comprising, in a cosmetically and/or dermatologically acceptable medium, an effective amount of at least one compound according to claim
 1. 18. A cosmetic and/or dermatological composition, comprising, in a cosmetically or dermatologically acceptable medium at least one compound according to claim
 1. 19. A composition according to claim 18, wherein said composition is in the form of a protective, treatment or care cream for the skin or the mucous membranes, for the face, for the hands or for the body, a protective or care body milk, a care or treatment lotion, gel or foam for the skin and the mucous membranes or for cleansing the skin, a soap or a cleansing bar.
 20. A composition according to claim 18, wherein said composition further comprises at least one product selected from antagonists of substance P and/or of Calcitonin Gene Related Peptide.
 21. A composition according to claim 18, wherein said composition comprises from 0.2 to 20% by weight, relative to the total weight of the composition, of said at least one compound. 